{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-25-000044","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.904586+00:00","generated_at":"2026-05-17T00:49:58.140925+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Halozyme Q3 revenue up 22%, raises 2025 guidance, CFO transition announced","bullets":["Q3 2025 revenue $354M (+22% YoY); royalty revenue $236M (+52% YoY); GAAP diluted EPS $1.43 (+36% YoY); non-GAAP diluted EPS $1.72 (+35% YoY).","Raises full-year 2025 guidance: total revenue $1,300-$1,375M, royalty $850-$880M, Adj. EBITDA $885-$935M, non-GAAP EPS $6.10-$6.50.","Agreed to acquire Elektrofi for $750M up-front plus up to $150M in milestones; expected close Q4 2025.","CFO Nicole LaBrosse to depart by March 30, 2026 or when successor hired; external search underway; departure not due to disagreement.","Two new indication approvals: DARZALEX SC for smoldering multiple myeloma in Europe; VYVDURA prefilled syringe in Japan."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-25-000044","json":"https://secwatch.observer/filing/0001159036-25-000044.json","markdown":"https://secwatch.observer/filing/0001159036-25-000044.md","text":"https://secwatch.observer/filing/0001159036-25-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000044/0001159036-25-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000044/halo-20251103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:49:58.140925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}